CN1589793A - Application of tannic acid berberine in preparation of medicine for treating ulcero colonitis - Google Patents
Application of tannic acid berberine in preparation of medicine for treating ulcero colonitis Download PDFInfo
- Publication number
- CN1589793A CN1589793A CN 200410054779 CN200410054779A CN1589793A CN 1589793 A CN1589793 A CN 1589793A CN 200410054779 CN200410054779 CN 200410054779 CN 200410054779 A CN200410054779 A CN 200410054779A CN 1589793 A CN1589793 A CN 1589793A
- Authority
- CN
- China
- Prior art keywords
- berberine tannate
- berberine
- medicine
- application
- colon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 229940093265 berberine Drugs 0.000 title claims abstract description 56
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 title claims abstract description 10
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 title abstract description 4
- 239000001263 FEMA 3042 Substances 0.000 title abstract description 4
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 title abstract description 4
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 title abstract description 4
- 229940033123 tannic acid Drugs 0.000 title abstract description 4
- 235000015523 tannic acid Nutrition 0.000 title abstract description 4
- 229920002258 tannic acid Polymers 0.000 title abstract description 4
- 210000001072 colon Anatomy 0.000 claims abstract description 26
- 239000002775 capsule Substances 0.000 claims abstract description 22
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 229920002253 Tannate Polymers 0.000 claims description 52
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 18
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 description 20
- 235000019698 starch Nutrition 0.000 description 20
- 239000008107 starch Substances 0.000 description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 14
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- 229910052708 sodium Inorganic materials 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 208000025865 Ulcer Diseases 0.000 description 9
- 231100000397 ulcer Toxicity 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 206010013786 Dry skin Diseases 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 239000007779 soft material Substances 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 201000002516 toxic megacolon Diseases 0.000 description 2
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067993 Mucosal necrosis Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 208000014965 pancolitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 206010036784 proctocolitis Diseases 0.000 description 1
- 208000017048 proctosigmoiditis Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the application of tannic acid berberine in preparation of medicine for treating ulcero colonitis. The application dosage range is 0.1 to 3 g, preferably 0.3 to 1.5 g. The invention provides medicine combination for treating ulcero colonitis using tannic acid berberine as active ingredient, wherein the combination can be tablet, capsule, granule, colon release capsule or oral liquid, preferably colon release capsules.
Description
Technical field
The present invention relates to the application of berberine tannate in the medicine of preparation treatment ulcerative colitis.
Background technology
Ulcerative colitis (UC) is the very not clear and definite rectum of a kind of reason and the chronic inflammation disease of colon.Clinical in stomachache, diarrhoea, mucus or the bloody purulent stool of outbreak, protracted course of disease are feature repeatedly.Fibercolonscopy shows proctitis, proctosigmoiditis, a left side or right hemicolon inflammation, regional colitis, pancolitis and false polyp etc.
The inventor finds that by great deal of experimental berberine tannate has good therapeutical effect to ulcerative colitis.
Summary of the invention
The invention provides the application of berberine tannate in the medicine of preparation treatment ulcerative colitis, its application dose scope is 0.1-3g; The preferred dose scope is 0.3-1.5g.
The invention provides with the berberine tannate is the pharmaceutical composition of active component, its dosage unit is 0.05-1.0g, be preferably 0.15-0.3g, it can exist with the form of tablet, capsule, granule, oral liquid or colon release capsule, is preferably the colon release capsule.
Berberine tannate pharmaceutical composition provided by the invention can adopt pharmaceutically conventional preparation method to be prepared from.
The present invention understands that by the test illustration berberine tannate is in the purposes for preparing the medicine for the treatment of the soup colitis of bursting and the effect power of different dosage form.
The specific embodiment
Embodiment 1: berberine tannate colon release capsule (specification: 0.15g)
Prescription: berberine tannate 150.0g
Starch 32.0g
Carboxymethyl starch sodium 18.0g
3%PVP
K30Aqueous solution is an amount of
Make 1000 capsules altogether
Operation: cross 100 mesh sieves after taking by weighing the abundant mix homogeneously of berberine tannate, starch and carboxymethyl starch sodium of recipe quantity, add 3% PVP
K30Aqueous solution is made soft material in right amount, and 28 mesh sieves are granulated, about 3 hours of 60 ℃ of dryings, and 26 mesh sieve granulate are adorned colon colloidal sol capsule No. 1, regulate the about 200mg of loading amount, promptly.
Embodiment 2: berberine tannate colon release capsule (specification: 0.3g)
Prescription: berberine tannate 300.0g
Starch 32.0g
Carboxymethyl starch sodium 18.0g
3%PVP
K30Aqueous solution is an amount of
Make 1000 capsules altogether
Operation: cross 100 mesh sieves after taking by weighing the abundant mix homogeneously of berberine tannate, starch and carboxymethyl starch sodium of recipe quantity, add 3% PVP
K30Aqueous solution is made soft material in right amount, and 28 mesh sieves are granulated, about 3 hours of 60 ℃ of dryings, and 26 mesh sieve granulate are adorned colon colloidal sol capsule No. 00, regulate the about 350mg of loading amount, promptly.
Embodiment 3: berberine tannate colon release capsule (specification: 0.05g)
Prescription: berberine tannate 50.0g
Starch 32.0g
Carboxymethyl starch sodium 18.0g
3%PVP
K30Aqueous solution is an amount of
Make 1000 capsules altogether
Operation: cross 100 mesh sieves after taking by weighing the abundant mix homogeneously of berberine tannate, starch and carboxymethyl starch sodium of recipe quantity, add 3% PVP
K30Aqueous solution is made soft material in right amount, and 28 mesh sieves are granulated, about 3 hours of 60 ℃ of dryings, and 26 mesh sieve granulate are adorned colon colloidal sol capsule No. 4, regulate the about 100mg of loading amount, promptly.
Embodiment 4: berberine tannate tablet (specification 0.15g)
Prescription: berberine tannate 150.0g
Icing Sugar 35.0g
Carboxymethyl starch sodium 13.0g
3%PVP
K30Aqueous solution is an amount of
Magnesium stearate 2.0g
Make 1000 altogether
Cross 100 mesh sieves after taking by weighing the abundant mix homogeneously of berberine tannate, Icing Sugar, carboxymethyl starch sodium of recipe quantity, add 3%PVP
K30Aqueous solution is made soft material in right amount, and 20 mesh sieves are granulated, 60 ℃ of dryings 3 hours, and 18 mesh sieve granulate add the magnesium stearate of recipe quantity, φ 10mm scrobicula stamping behind the mix homogeneously, the heavily about 200mg of adjustment sheet, promptly.
Embodiment 5: berberine tannate tablet (specification 1.0g)
Prescription: berberine tannate 1000.0g
Icing Sugar 105.0g
Carboxymethyl starch sodium 39.0g
3%PVP
K30Aqueous solution is an amount of
Magnesium stearate 6.0g
Make 1000 altogether
Operation: cross 100 mesh sieves after taking by weighing the abundant mix homogeneously of berberine tannate, Icing Sugar, carboxymethyl starch sodium of recipe quantity, add the 3%PVPK30 aqueous solution and make soft material in right amount, 20 mesh sieves are granulated, 60 ℃ of dryings 3 hours, 18 mesh sieve granulate, the magnesium stearate of adding recipe quantity, φ 10mm scrobicula stamping behind the mix homogeneously, the heavily about 1200mg of adjustment sheet, promptly.
Embodiment 6: berberine tannate tablet (specification 0.5g)
Prescription: berberine tannate 500.0g
Icing Sugar 70.0g
Carboxymethyl starch sodium 26.0g
3%PVP
K30Aqueous solution is an amount of
Magnesium stearate 4.0g
Make 1000 altogether
Operation: cross 100 mesh sieves after taking by weighing the abundant mix homogeneously of berberine tannate, Icing Sugar, carboxymethyl starch sodium of recipe quantity, add the 3%PVPK30 aqueous solution and make soft material in right amount, 20 mesh sieves are granulated, 60 ℃ of dryings 3 hours, 18 mesh sieve granulate, the magnesium stearate of adding recipe quantity, φ 10mm scrobicula stamping behind the mix homogeneously, the heavily about 600mg of adjustment sheet, promptly.
Embodiment 7: berberine tannate tablet (specification 0.05g)
Prescription: berberine tannate 50.0g
Icing Sugar 135.0g
Carboxymethyl starch sodium 15.0g
3%PVP
K30Aqueous solution is an amount of
Magnesium stearate 2.0g
Make 1000 altogether
Operation: cross 100 mesh sieves after taking by weighing the abundant mix homogeneously of berberine tannate, Icing Sugar, carboxymethyl starch sodium of recipe quantity, add the 3%PVPK30 aqueous solution and make soft material in right amount, 20 mesh sieves are granulated, 60 ℃ of dryings 3 hours, 18 mesh sieve granulate, the magnesium stearate of adding recipe quantity, φ 10mm scrobicula stamping behind the mix homogeneously, the heavily about 200mg of adjustment sheet, promptly.
Test example 1, berberine tannate are to the effect of experimental rat ulcerative colitis
(1), the making of UC model and pathologic finding
Get 72 rats, body weight 220-250g, female, fasting 16 hours, 10% chloral hydrate anesthesia, abdomen is opened in the abdominal part sterilization, clamps with the bulldog clamp of sterilizing apart from returning the about 4 centimeters colons of cecum, colonic injects 7% acetic acid 1.0ml, uses the 5ml normal saline flushing after 15 seconds, sews up abdominal part.In second day random packet, 12 every group, be respectively berberine tannate colon administration group, berberine tannate is irritated the high, medium and low dosage group of stomach, sulfasalazine (SASP) group and model group (giving normal saline).Administering mode except that tannic acid berberine colon administration group from anum administration, other respectively organize gastric infusion.Administration volume: 1.0ml/200g.Below respectively organize and be administered once every day, successive administration 7 days, rat is put to death in the experiment back that finishes, and observes the degree of injury apart from anus 6～8cm place colon, and gets wherein 0.5cm pathological changes intestinal tissue with 4% formaldehyde fixed, the routine paraffin wax section, HE dyes and light microscopy checking.
(2), colonic mucosal injury index (CMDI) and histopathology scoring (HS) standard
Colonic mucosal injury index (CMDI): 0 minute: not damaged; 1 minute: mild hyperaemia, edema, surface light, no erosion or ulcer; 2 minutes: congestion and edema, the coarse granular sensation that is of mucosa has erosion or intestinal adhesion; 3 minutes: the height congestion and edema, there are necrosis and ulcer in the surface, the maximum vertical footpath＜1cm of ulcer, intestinal wall thickens or there are necrosis and inflammation in the surface; 4 minutes: the height congestion and edema, mucosal necrosis and ulcer, the maximum vertical footpath＞1cm of ulcer, or wall bowel necrosis, toxic megacolon cause death entirely.
Histopathology scoring (HS) standard: HS standard reference document also improves slightly: 1. acute inflammation cellular infiltration, 0 minute: do not have 1 fen: slightly increase by 2 fens: significantly increase; 2. chronic inflammation cellular infiltration, 0 minute: do not have 1 fen: slightly increase by 2 fens: significantly increase; 3. fibrin deposition, 0 minute: do not have 1 minute: have; 4. edema under the mucosa, 0 minute: do not have 1 minute: lamellar, 2 minutes: plocoid; 5. epithelium necrosis, 0 minute: do not have 1 fen: limitation, 2 minutes: extensively; 6. epithelium ulcer, 0 minute: do not have 1 minute: have.
(3), statistical procedures: all measurement datas are all represented with X ± S, relatively adopt the t check between group.
(4), result of the test
The result shows (table 1): rat the feces character promptly occurs and changes after acetic acid treatment, the seriality pathological changes of human ulcerative colitis appears being similar in colon, show as mucosa height congestion and edema, there are necrosis and ulcer in the surface, and part animal even generation toxic megacolon cause death.The mucosa pathological change shows as mucosa and the obvious edema of tela submucosa, fibrin precipitation, neutrophil infiltration, occurs epithelium necrosis and ulcer when serious.But berberine tannate is irritated stomach dose dependent ground and is alleviated the CMDI degree of acetic acid colitis rat, and the rat colon of improvement mucosa pathology damaging action is arranged, and shows that the rat colon mucosa injury that acetic acid is caused has significant protective effect.Berberine tannate colon administration group dosage and berberine tannate gastric infusion low dose group dosage identical (being 75mg/kg), and pharmacodynamics effect and berberine tannate gastric infusion high dose group (300mg/kg) are suitable.
Table 1 berberine tannate is to the influence of experimental rat ulcerative colitis
Group dosage (mg/kg) CMDI HS
Model group 2.91 ± 0.67 4.25 ± 0.78
5-ASA 100 1.52±0.93 3.20±0.51
Berberine tannate colon administration group 75 1.20 ± 0.35
*3.21 ± 1.06
*
Berberine tannate is irritated stomach high dose group 300 1.11 ± 0.38
*3.12 ± 1.16
*
Berberine tannate is irritated dosage group 150 1.78 ± 0.89 in the stomach
*3.40 ± 1.10
*
Berberine tannate is irritated stomach low dose group 75 2.63 ± 0.84 3.84 ± 1.8
Annotate:
*P＜0.05,
*Compare with model group P＜0.01.
The different preparation administrations of test example 2, berberine tannate are to the effect of ulcerative colitis
Selection is through fibercolonscopy, and clinical diagnosis is ulcerative colitis patient 60 examples (age 35-50 years), is divided into 3 groups at random, every group 20 example, and the administration cycle is 1 month.The 1st group gives berberine tannate common oral preparation (tablet), and dosage is 0.9g, tid; The 2nd group gives berberine tannate colon enteric coated capsule, dosage 0.3g, tid; The 3rd group gives Olsalazine, 0.5g, tid.All capable colonoscopy before and after the administration.
The therapeutic effect evaluation of ulcerative colitis: 1. alleviate fully: line up shape stool≤3 times every day, no hemafecia, body temperature is normal, and the General Symptoms of ulcerative colitis disappears, lab testing is roughly normal, and the microscopically that colonoscope reaches biopsy down shows the evidence that does not all have acute and chronic inflammation; 2. part is alleviated: above each point all has improvement in various degree, does not alleviate but reach fully; 3. state of an illness no change: does not promptly all have obviously change under the clinical and colonoscope before and after the treatment; 4. sb.'s illness took a turn for the worse: performance further increases the weight of under the clinical and colonoscope in treatment back.
During therapeutic evaluation, add up with invalid (comprise and treat back state of an illness no change or deterioration) according to treatment effective (alleviating fully or the part alleviation after comprising treatment).The result shows, effective 8 examples of oral common berberine tannate preparation (tablet) group, invalid 12 examples; Oral berberine tannate colon enteric coated capsule group, effective 18 examples, invalid 2 examples; Oral Olsalazine group, effective 16 examples, invalid 4 examples.Untoward reaction does not all appear in oral berberine tannate ordinary preparation and berberine tannate colon enteric coated capsule group; Oral Olsalazine group, feeling sick appears in 3 examples, and 1 example diarrhoea occurs and increases the weight of.
Above result shows that berberine tannate is an effectively medicine of treatment ulcerative colitis.Its therapeutic effect is relevant with the partial drug level of ulcer.Oral berberine tannate colon enteric coated capsule has better therapeutic effect to ulcerative colitis.The berberine tannate colon administration obviously is better than oral ordinary preparation to the curative effect of ulcerative colitis; And there is not tangible untoward reaction.
Claims (7)
1. the application of berberine tannate in the medicine of preparation treatment ulcerative colitis.
2. application according to claim 1, its using dosage scope is 0.1-3g.
3. application according to claim 2, its preferred using dosage scope is 0.3-1.5g.
4. be the pharmaceutical composition of active component with the berberine tannate, its dosage unit is 0.05-1.0g.
5. pharmaceutical composition according to claim 4, its dosage unit is preferably 0.15-0.3g.
6. according to claim 4 or 5 described pharmaceutical compositions, it can exist with the form of tablet, capsule, granule, oral liquid or colon release capsule.
7. pharmaceutical composition according to claim 6, it is preferably the colon release capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410054779 CN1589793A (en) | 2003-07-24 | 2004-07-21 | Application of tannic acid berberine in preparation of medicine for treating ulcero colonitis |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03132959.4 | 2003-07-24 | ||
| CN03132959 | 2003-07-24 | ||
| CN 200410054779 CN1589793A (en) | 2003-07-24 | 2004-07-21 | Application of tannic acid berberine in preparation of medicine for treating ulcero colonitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1589793A true CN1589793A (en) | 2005-03-09 |
Family
ID=34620999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410054779 Pending CN1589793A (en) | 2003-07-24 | 2004-07-21 | Application of tannic acid berberine in preparation of medicine for treating ulcero colonitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1589793A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014530883A (en) * | 2011-10-24 | 2014-11-20 | インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ メディカル サイエンシズ | Protoberberine biological alkaloid derivatives and their use to inhibit ulcerative colitis |
| CN104211709A (en) * | 2013-05-29 | 2014-12-17 | 中国医学科学院药物研究所 | Coptisine alkaloid derivatives and application thereof on preventing ulcerative colitis |
| CN107125461A (en) * | 2016-02-29 | 2017-09-05 | 湖南晶天科技实业有限公司 | A kind of feed addictive enteric coating tannin acid derivative and a kind of feed |
| CN109464417A (en) * | 2018-12-19 | 2019-03-15 | 中国药科大学 | A kind of desmethylene berberine hydrochloride enteric-coated capsule and preparation method thereof |
| US20210032265A1 (en) * | 2012-04-16 | 2021-02-04 | Case Western Reserve University | Compositions and methods of modulating 15-pgdh activity |
| US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| CN119367309A (en) * | 2024-11-05 | 2025-01-28 | 博济医药科技股份有限公司 | Berberine tannate oral preparation and preparation method thereof |
| US12336982B2 (en) | 2018-11-21 | 2025-06-24 | Rodeo Therapeutics Corporation | Compositions and methods of modulating short-chain dehydrogenase activity |
-
2004
- 2004-07-21 CN CN 200410054779 patent/CN1589793A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014530883A (en) * | 2011-10-24 | 2014-11-20 | インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ メディカル サイエンシズ | Protoberberine biological alkaloid derivatives and their use to inhibit ulcerative colitis |
| EP2789612A4 (en) * | 2011-10-24 | 2015-12-16 | Inst Materia Medica Cams | BIOLOGICAL ALKALOID DERIVATIVES OF PROTOBERBERIN AND THEIR USE FOR INHIBITING ULCERATIVE COLITIS |
| US20210032265A1 (en) * | 2012-04-16 | 2021-02-04 | Case Western Reserve University | Compositions and methods of modulating 15-pgdh activity |
| CN104211709A (en) * | 2013-05-29 | 2014-12-17 | 中国医学科学院药物研究所 | Coptisine alkaloid derivatives and application thereof on preventing ulcerative colitis |
| CN104211709B (en) * | 2013-05-29 | 2018-09-25 | 中国医学科学院药物研究所 | The purposes of coptisine Alkaloid derivative and its anti-ulcerative colitis |
| CN107125461A (en) * | 2016-02-29 | 2017-09-05 | 湖南晶天科技实业有限公司 | A kind of feed addictive enteric coating tannin acid derivative and a kind of feed |
| US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| US12336982B2 (en) | 2018-11-21 | 2025-06-24 | Rodeo Therapeutics Corporation | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN109464417A (en) * | 2018-12-19 | 2019-03-15 | 中国药科大学 | A kind of desmethylene berberine hydrochloride enteric-coated capsule and preparation method thereof |
| CN119367309A (en) * | 2024-11-05 | 2025-01-28 | 博济医药科技股份有限公司 | Berberine tannate oral preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5502807B2 (en) | Colonic laxative composition comprising a soluble binder | |
| CN1589793A (en) | Application of tannic acid berberine in preparation of medicine for treating ulcero colonitis | |
| CN1679755A (en) | Preparation method of traditional Chinese medicine suppository for treating women's chronic cervicitis | |
| CN101028490A (en) | Chinese medicine for treating acne | |
| CN1155380C (en) | Application of sophocarpidine oxide in preparing medicine to treat ulcerative colitis | |
| CN1836693A (en) | Chinese medicine composition for treating arthritis and preparing method thereof | |
| CN1709243A (en) | Vagina medicine containing ebselen and its use | |
| CN1289505C (en) | New compound,its preparation method, medicine preparation using said compound as active component, its action and application | |
| CN100339126C (en) | Chinese traditional medicine for preventing and treating biliary tract inflammation and its preparation process | |
| CN101032482A (en) | Compound preparation resisting coxsackie virus and herpesvirus | |
| CN104888153A (en) | Traditional Chinese medicine preparation for treating hepatic hemangioma and preparation method therefor | |
| CN1233313C (en) | Gel agent for treating acne and its preparation method | |
| CN1771981A (en) | Pile ointment | |
| CN1548065A (en) | Compound Chinese medicine for treating chronic pulvic infection and prepn process of its prepn forms | |
| CN1915345A (en) | Traditional Chinese medicinal preparation for improving liver cirrhosis ascites and its preparation method | |
| CN1327386A (en) | Anti-HIV infection agent and treatment method for HIV infection | |
| CN1248697C (en) | Medicinal composition for treating chronic enteritis and its preparing process | |
| CN100344319C (en) | Chinese medicine composition for treating urogenital system disease and its preparing method and use | |
| CN1213749C (en) | Prepn. of obakulactone contd. medicine for treating hemorrhoid, and its use | |
| CN1676130A (en) | Water-soluble medicine sublingual-medicating formulation | |
| CN1569085A (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN1850224A (en) | Medicine for treating scald and burn and preparing method | |
| CN1275647C (en) | Application of neutral proteinase in preparing medicine for anorectal diseases and the medicine | |
| CN119345223A (en) | Pharmaceutical composition containing inulin and fucoidan, drug combination and application thereof | |
| WO2023242750A1 (en) | Novel combination based on salified butyric acid and yeasts, compositions containing it and their use in therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |